Nkarta To Participate In September Investor Conferences
September 16, 2026
H.C. Wainwright 28th Annual Global Investment Conference
New York, NY
10:30 a.m. ET – fireside chat
September 23, 2026
Stifel 2026 Virtual Immunology and Inflammation Forum
12:30 p.m. ET – fireside chat
A simultaneous webcast of both events will be available on the Investors section of Nkarta's website,, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company's website at .
Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment